相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma: 7-year follow-up results
Kensei Tobinai et al.
CANCER SCIENCE (2010)
Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non-Hodgkin's Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study
Marinus H. J. van Oers et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells
Andres Lopez-Albaitero et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan
Frederic Bibeau et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Follicular Lymphoma in the United States: First Report of the National LymphoCare Study
Jonathan W. Friedberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Immunophenotyping of mature B-cell non Hodgkin lymphoma involving bone marrow and peripheral blood: critical analysis and insights gained at a tertiary care cancer hospital
Sumeet Gujral et al.
LEUKEMIA & LYMPHOMA (2009)
Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma
Robert Marcus et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer
Antonino Musolino et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma
M Ogura et al.
CANCER SCIENCE (2006)
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
W Hiddemann et al.
BLOOD (2005)
New treatment options have changed the survival of patients with follicular lymphoma
RI Fisher et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Single agent rituximab in patients with follicular or mantle cell lymphoma:: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system:: a study of the Swiss Group for Clinical Cancer Research (SAKK)
A Ghielmini et al.
ANNALS OF ONCOLOGY (2005)
Improved survival of follicular lymphoma patients in the United States
WT Swenson et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Maximizing therapeutic benefit of rituximab: Maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma - A randomized phase II trial of the minnie pearl cancer research network
JD Hainsworth et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma
R Marcus et al.
BLOOD (2005)
Follicular lymphoma international prognostic index
P Solal-Céligny et al.
BLOOD (2004)
Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy:: 9-year follow-up
MS Czuczman et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma
K Tobinai et al.
ANNALS OF ONCOLOGY (2004)
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma
WK Weng et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Monoclonal antibody therapy for B-Cell lymphoma: Clinical trials of an anti-CD20 monoclonal antibody for B-cell lymphoma in Japan
K Tobinai
INTERNATIONAL JOURNAL OF HEMATOLOGY (2002)
Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study
T Igarashi et al.
ANNALS OF ONCOLOGY (2002)
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
G Cartron et al.
BLOOD (2002)
Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation
P Colombat et al.
BLOOD (2001)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
分享论文
